Covaxin Trials: What 81% "Interim Efficacy" Means
Bharat Biotech has claimed in a press release that its Covid-19 vaccine candidate, Covaxin, showed 81% efficacy in the "first interim analysis" of phase-3 trials.
Newsclick Production

Bharat Biotech has claimed in a press release that its Covid-19 vaccine candidate, Covaxin, showed 81% efficacy in the "first interim analysis" of phase-3 trials. Scientist Satyajit Rath here simplifies the science and process involved in clinical trials of vaccines.

Get the latest reports & analysis with people's perspective on Protests, movements & deep analytical videos, discussions of the current affairs in your Telegram app. Subscribe to NewsClick's Telegram channel & get Real-Time updates on stories, as they get published on our website.